Catheter Precision lands Cardinal Health deal and Johns Hopkins order
Catheter Precision (NYSE American: VTAK) has announced three commercial milestones for its LockeT suture retention device and VIVO non-invasive imaging system, signalling a broadening of the Fort Mill, South Carolina company's distribution reach across the US and Europe.
The company received its first purchase order for LockeT through Cardinal Health, one of the largest medical product distributors in the United States. Cardinal Health's medical products business serves approximately 90% of US hospitals, and the agreement gives Catheter Precision access to a supply chain that smaller device companies typically take years to reach independently.
Hospital adoption and European expansion
Johns Hopkins Hospital in Baltimore placed a separate first order for LockeT. For a device still building its clinical profile, an initial order from a globally recognised academic medical centre carries meaningful third-party validation, as teaching hospitals tend to be conservative adopters that document outcomes rigorously, and their purchasing decisions are closely watched by peer institutions.
On the international side, Catheter Precision signed a placement contract for the VIVO system with a hospital in Germany. The company did not name the institution. Germany is among the highest-volume electrophysiology markets in Europe, with a large installed base of EP labs and a reimbursement environment that has historically supported procedural innovation, making it a logical first foothold for a US device maker seeking European scale.
Chief executive David Jenkins said the three milestones together demonstrate progress across both product lines. "Securing our first Cardinal Health order grants us immediate access to an extensive domestic distribution network to drive broader market adoption," he said. "Concurrently, our milestone order with Johns Hopkins validates our clinical offering, while our new VIVO contract in Germany underscores steady international demand."
Market context
The cardiac electrophysiology device market has attracted sustained investment over recent years, driven by growing global prevalence of atrial fibrillation and ventricular arrhythmias and the parallel expansion of ablation-based treatment. Larger incumbents such as Abbott, Biosig Technologies and Acutus Medical have competed in imaging and mapping, while the closure and wound-management niche where LockeT sits has seen interest from both established distributors and smaller specialist players.
For a company of Catheter Precision's scale, multi-channel distribution agreements are often more commercially decisive than product development milestones in the near term. The Cardinal Health route to market, if it converts to repeating purchase volumes, could meaningfully change the revenue trajectory of LockeT without requiring the company to expand its direct salesforce at equivalent cost.
Investors will be watching for order-volume data and any conversion from placement to purchase for the German VIVO unit, as single-system placements in new markets are more indicative of commercial intent than of established demand. The company said its focus remains on scaling through top-tier health systems, direct enterprise relationships, and international distribution partners, but provided no forward revenue guidance alongside the announcement.